Global Favipiravir Market Overview:
Global Favipiravir Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2024 as the base year.
Global Favipiravir Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Favipiravir involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Favipiravir Market:
The Favipiravir Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Favipiravir Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Favipiravir Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Favipiravir market has been segmented into:
Original Drug
Generic Drug
By Application, Favipiravir market has been segmented into:
Influenza Viruses
HIV
SARS
Ebola
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Favipiravir market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Favipiravir market.
Top Key Players Covered in Favipiravir market are:
Fujifilm Toyama Chemical
CSPC Pharmaceutical Group
Reyoung Pharmaceutical
Sihuan Pharmaceutical
Hisun Pharm
Dr. Reddy’s Laboratories Ltd.
Glenmark Pharmaceuticals Ltd.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Favipiravir Market by Type
4.1 Favipiravir Market Snapshot and Growth Engine
4.2 Favipiravir Market Overview
4.3 Original Drug
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Original Drug: Geographic Segmentation Analysis
4.4 Generic Drug
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Generic Drug: Geographic Segmentation Analysis
Chapter 5: Favipiravir Market by Application
5.1 Favipiravir Market Snapshot and Growth Engine
5.2 Favipiravir Market Overview
5.3 Influenza Viruses
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Influenza Viruses: Geographic Segmentation Analysis
5.4 HIV
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 HIV: Geographic Segmentation Analysis
5.5 SARS
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 SARS: Geographic Segmentation Analysis
5.6 Ebola
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Ebola: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Favipiravir Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 FUJIFILM TOYAMA CHEMICAL
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 CSPC PHARMACEUTICAL GROUP
6.4 REYOUNG PHARMACEUTICAL
6.5 SIHUAN PHARMACEUTICAL
6.6 HISUN PHARM
6.7 DR. REDDY’S LABORATORIES LTD.
6.8 GLENMARK PHARMACEUTICALS LTD.
Chapter 7: Global Favipiravir Market By Region
7.1 Overview
7.2. North America Favipiravir Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Original Drug
7.2.4.2 Generic Drug
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Influenza Viruses
7.2.5.2 HIV
7.2.5.3 SARS
7.2.5.4 Ebola
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Favipiravir Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Original Drug
7.3.4.2 Generic Drug
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Influenza Viruses
7.3.5.2 HIV
7.3.5.3 SARS
7.3.5.4 Ebola
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Favipiravir Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Original Drug
7.4.4.2 Generic Drug
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Influenza Viruses
7.4.5.2 HIV
7.4.5.3 SARS
7.4.5.4 Ebola
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Favipiravir Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Original Drug
7.5.4.2 Generic Drug
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Influenza Viruses
7.5.5.2 HIV
7.5.5.3 SARS
7.5.5.4 Ebola
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Favipiravir Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Original Drug
7.6.4.2 Generic Drug
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Influenza Viruses
7.6.5.2 HIV
7.6.5.3 SARS
7.6.5.4 Ebola
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Favipiravir Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Original Drug
7.7.4.2 Generic Drug
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Influenza Viruses
7.7.5.2 HIV
7.7.5.3 SARS
7.7.5.4 Ebola
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Favipiravir Scope:
|
Report Data
|
Favipiravir Market
|
|
Favipiravir Market Size in 2025
|
USD XX million
|
|
Favipiravir CAGR 2025 - 2032
|
XX%
|
|
Favipiravir Base Year
|
2024
|
|
Favipiravir Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Fujifilm Toyama Chemical, CSPC Pharmaceutical Group, Reyoung Pharmaceutical, Sihuan Pharmaceutical, Hisun Pharm, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd..
|
|
Key Segments
|
By Type
Original Drug
Generic Drug
By Applications
Influenza Viruses
HIV
SARS
Ebola
|
